ERBB2 and breast cancer: Trastuzumab-containing neoadjuvant chemotherapy (NC) has significantly changed the standard of care for locally advanced HER2-positive breast cancer (BC) patients, demonstrating the ability to increase pathological Complete Response (pCR) rates up to 65% [1].